NCT07644351Completed
A Real-world Study of Asciminib Effectiveness in Philadelphia Positive Acute Lymphoblastic Leukemia Patients
Asciminib Effectiveness in Real World Setting of Philadelphia Positive Acute Lymphoblastic Leukemia (Ph+ALL); a Retrospective Review Study of Patients From the Asciminib Managed Access Program (ASCERTAIN)
Source: ClinicalTrials.gov · Last updated 12 Jun 2026
Brief summary (registry, in English)
The aim of this study was to collect existing information from the medical charts of patients enrolled in the ongoing asciminib Managed Access Program (MAP) to better understand the effectiveness and safety of asciminib when used to treat adult patients with Ph+ ALL who are refractory, resistant or intolerant to available treatments.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 37 (actual)
- First submitted
- 8 Jun 2026
- Start date
- Dec 2024
- Primary completion date
- Sept 2025
- Lead sponsor
- Novartis Pharmaceuticals
- Diseases
- Acute lymphoblastic leukaemia
- NCT number
- NCT07644351
What you commit to
- Study type: Observational
- Participants enrolled: 37
- From Dec 2024 to the primary completion date, Sept 2025
- 18 sites in 12 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Age
- Age \< 18 years at the time of initiating asciminib treatment.
Who the study is looking for
- Adult patients enrolled in the asciminib MAP.
- Diagnosis of Ph+ ALL.
- Patients received at least one dose of asciminib through the asciminib MAP.
- Appropriate approval obtained for the use of patient data including:
- Signed informed consent form (ICF), or
- ICF waiver granted by an Institutional review board/Independent Ethics Committee (IRB/IEC).
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (18)
Sites in registry order. Pick your city on the disease page to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.